Clinical trials: latest news

Clinical trials resources

  • Clinical trials

    A clinical trial is a study in which a new treatment is assessed.There are legal requirements on how a trial should be run.If you choose to join a...

    From: Factsheets

    Information level Level 2
  • Thinking about joining a clinical trial?

    Before you make a decision about joining a clinical trial, make sure you fully understand what’s involved.There will be benefits and risks to joining any clinical trial.Discuss...

    From: Factsheets

    Information level Level 2

Clinical trials features

Clinical trials in your own words

Clinical trials news from aidsmap

More news

Clinical trials news selected from other sources

  • Community Recommendations for Clinical Research Involving Antiretroviral Treatment Interruptions in Adults

    Scientists working to develop a cure for HIV infection sometimes need to conduct clinical trials in which participants are asked to temporarily interrupt ART, which contradicts the recommendations and guidelines for people with HIV under medical care.

    15 November 2018 | TAG
  • How to evaluate PrEP and vaccines: urgency for next generation compounds

    Several presentations at R4P 2018 looked at the new challenges of evaluating efficacy of new PrEP and vaccine candidates.

    05 November 2018 | HIV i-Base
  • STEPS V: HIV cure community workshop in Glasgow

    STEPS, a community initiative to design the pathway to a long-term remission of HIV infection, has reached its 5th edition in Glasgow. This year the theme of the meeting that was held just before the opening of the HIV Drug Therapy Congress was ‘socio-behavioural science and ethics around HIV cure research’.

    01 November 2018 | EATG
  • Making Clinical Trials of PrEP More Inclusive of Women, No Matter Their Pregnancy Status

    Three new trials of HIV prevention drugs seek to answer directly a question that researchers inside and outside the field of HIV have explicitly avoided for years: How do drugs work -- and are they safe -- in pregnant and breastfeeding women?

    01 October 2018 | The Body Pro
  • Meta-analyses were supposed to end scientific debates. Often, they only cause more controversy

    Although the basic rules of the meta-analysis are simple, researchers must make many choices along the way, allowing conscious or unconscious biases to creep in.

    19 September 2018 | Science
  • FRESH program combines basic science with social benefits for women at risk of HIV

    A program established by the Ragon Institute of MGH, MIT and Harvard is addressing the persistently elevated risk of HIV infection among young women in South Africa from two angles -- first, investigating biological factors that modulate infection risk and the early immunologic events following viral exposure, and second, alleviating the socioeconomic factors that limit opportunities for young women, the group at greatest risk in the region hit hardest by the HIV epidemic.

    16 September 2018 | Eurekalert Inf Dis
  • Half of Europe's clinical trials fail to report results despite EU rule

    Almost half of all European-registered clinical trials - in which scientists test drug treatments, interventions or therapies in humans - have breached EU rules by failing to report results, according to an analysis published on Thursday.

    13 September 2018 | Reuters
  • We Love the Jargon, We Hate the Jargon!

    This blog post by Angelo Kaggwa-Katumba and Kay Marshall talks about the essential work of connecting journalists and researchers and how advocates are the linchpin.

    20 July 2018 | AVAC
  • Superior AIDS-Kaposi’s Sarcoma Treatment Identified

    A clinical trial funded by the National Institute of Allergy and Infectious Diseases (NIAID) and National Cancer Institute comparing three chemotherapy regimens in combination with antiretroviral treatment (ART) for treatment of advanced AIDS-Kaposi’s sarcoma patients in Africa and South America has ended early. Interim data showed that participants who were treated with paclitaxel plus ART had better tumor outcomes than participants who received the other treatment regimens.

    27 June 2018 | National Institute of Allergies and Infectious Diseases (NIAID)
  • NHS England considers expanding PrEP trial - NAT comment

    Deborah Gold, Chief Executive of NAT (National AIDS Trust) said: “This proposed trial expansion, from 10,000 to 13,000 participants, is essential and we urge NHS England to confirm the decision urgently. This expansion was first proposed by NAT as necessary to estimate accurately the likely long-term needs of a routinely commissioned PrEP programme and it’s great news that this is now on the table.

    18 June 2018 | National AIDS Trust
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.